Contrast-enhanced Ultrasound Evaluation of Chemoembolization
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of this trial is to evaluate the sensitivity and specificity of 2D and
4D contrast enhanced ultrasound for monitoring transarterial chemoembolization (TACE)
response 1-2 weeks and 1 month post treatment as an alternative to contrast-enhanced magnetic
resonance (MRI) or computed tomography (CT) imaging
Phase:
Phase 3
Details
Lead Sponsor:
Sidney Kimmel Cancer Center at Thomas Jefferson University Thomas Jefferson University
Collaborators:
GE Healthcare Lantheus Medical Imaging National Institutes of Health (NIH) University of California, San Diego Vanderbilt University Vanderbilt University Medical Center